Ultime notizie per Centene (NYSE:CNC) Azioni

Centene

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

Conduit Capital Ltd

Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

CHINA TELETECH HLDGS INC by China Teletech Holding, Inc.

China Teletech Holding Inc

<p>Deep-pocketed investors have adopted a bearish approach towards Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CNC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Centene. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 19% leaning bullish and 76% bearish. Among these notable options, 15 are puts, totaling $4,405,390, and 6 are calls, amounting to $307,439.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $67.5 for Centene during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Centene's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Centene's whale trades within a strike price range from $55.0 to $67.5 in the last 30 days. </p>
<h3>Centene 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729197113_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$3.3</td>
<td>$66.00</td>
<td>$1.6M</td>
<td>11.9K</td>
<td>8.9K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$1.1</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$55.00</td>
<td>$730.0K</td>
<td>0</td>
<td>7.6K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$66.00</td>
<td>$330.1K</td>
<td>11.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.2</td>
<td>$2.5</td>
<td>$3.0</td>
<td>$66.00</td>
<td>$300.0K</td>
<td>11.9K</td>
<td>11.9K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.4</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$66.00</td>
<td>$273.6K</td>
<td>11.9K</td>
<td>3.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Centene</h3>
<p>Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.</p>
<p>Having examined the options trading patterns of Centene, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Centene Standing Right Now?</h3>
<ul>
<li>With a volume of 14,571,018, the price of CNC is down -8.8% at $63.2. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>What Analysts Are Saying About Centene</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $90.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $90.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $90. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Centene with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Centene Options Trading: A Deep Dive into Market Sentiment

<p><strong>Centene's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has fallen 18.84% since its last report. The company recently reported that it has <strong>7.80 million shares sold short</strong>, which is 1.68% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.92 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Centene Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729179912_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Centene has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.11%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Looking Into Centene's Recent Short Interest

WIIM

Shares of health insurance stocks are trading lower in sympathy with Elevance Health, which reported a Q3 earnings miss and issued soft FY24 guidance.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurers are trading lower in sympathy with UnitedHealth, which reported Q3 financial results and lowered the upper end range of annual EPS outlook.

<p><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4277602-1&amp;h=4074998618&amp;u=https%3A%2F%2Fwww.centene.com%2F&amp;a=Centene+Corporation">Centene Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4277602-1&amp;h=607808981&amp;u=https%3A%2F%2Fwww.mimeridian.com%2F&amp;a=Meridian+Health+Plan+of+Michigan%2C+Inc.">Meridian Health Plan of Michigan, Inc.</a>&nbsp;("Meridian"), has been selected by the Michigan Department of Health and Human Services (MDHHS) to provide highly integrated Medicare and Medicaid services for dually eligible Michiganders through a Highly Integrated Dual Eligible Special Needs Plan (HIDE SNP). The plan will launch on Jan. 1, 2026, when Michigan's MI Health Link pilot program transitions from a Medicare-Medicaid Plan (MMP) to MI Coordinated Health, a HIDE SNP in coordination with the Centers for Medicare and Medicaid Services (CMS).</p>


News

Contracts

Centene's Meridian Health Plan Of Michigan Awarded Contract To Serve Dual Eligibile Medicare And Medicaid Members In Michigan

<p>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 5.29% on an annualized basis producing an average annual return of 13.91%. Currently, Centene has a market capitalization of $38.08 billion. </p>
<p><strong>Buying $100 In CNC:</strong> If an investor had bought $100 of CNC stock 20 years ago, it would be worth <strong>$1,305.23</strong> today based on a price of $72.39 for CNC at the time of writing.</p>
<h3>Centene's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680441_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Centene 20 Years Ago Would Be Worth Today

<p>This represents meaningful progress and is consistent with internal expectations despite higher than industry-anticipated cut point changes. Additionally, it is appealing TTY results with CMS.</p>
<p>The Centers for Medicare and Medicaid Services (CMS) issued 2025 Medicare Advantage Star Ratings on October 10, 2024.&nbsp;</p>


Centene Has Approximately 46% Of Its Medicare Advantage Membership Enrolled In Plans Rated 3.5 Stars Or Higher Vs. Approximately 23% Prior Year - Filing

CLOV

EHTH

ELEV

GOCO

Biden-Harris Administration Proposes Medicare $2 Drug List Model To Lower Prescription Costs; CMS Seeks Feedback On Sample Drug List And Outreach With Voluntary Participation For Part D Sponsors Starting As Early As Jan 2027; Model To Include Drugs For Common Conditions With Periodic Updates Based On New Generics, Clinical Indications, And Pricing Trends

<p>Shares of&nbsp;<strong>Humana Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) have dropped 30.2% over the past month to close at $240.03 on Friday. The steep declines last week have pushed the stock&#39;s price closer to the lower end of its 52-week range of $213.31-$530.54. Having underperformed its peers like&nbsp;<strong>Molina Healthcare, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/moh#NYSE">MOH</a>) and <strong>Centene Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnc#NYSE">CNC</a>), the overall industry, and the S&amp;P 500, the company&#39;s current share price seems an excellent opportunity to build a position in a renowned HMO company. After all, you would much rather buy closer to the low than the high, right?&nbsp;</p>
<h2>One-Month Price Performance</h2>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e4/80609.jpg?v=334232142" style="border-style:solid; border-width:1px; height:310px; width:600px" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>HUM is trading below its 50 and 200-day moving averages, indicating a bearish outlook. Buying closer to the low can be attractive, but context matters - let&#39;s explore further.</p>
<h2>HUM&#39;s Falling Stars</h2>
<p>HUM experienced its worst share price fall since the financial crisis due to losing high-quality ratings on its major Medicare Advantage plans, which generate substantial revenue. The news slashed its star-rated membership from 94% to around 25%, triggering a selloff that wiped out a massive chunk of its market value.</p>
<p>This has not only affected Humana but also rippled through the broader health insurance sector. The health insurer, like many others, is already facing growing medical costs and tighter reimbursements from the government. This latest development is bound to affect its profit levels.</p>
<h2>Analysts Downgrade HUM&#39;s Earnings Estimates</h2>
<p>Reflecting the negative sentiment around Humana, the Zacks Consensus Estimate for earnings per share has seen downward revisions. The consensus estimate for 2024 adjusted earnings for HUM is currently pegged at $16.12 per share, indicating a 38.2% year-over-year decline. Over the past four quarters, its average earnings surprise is at negative 2.5%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9b/80608.jpg?v=386647277" style="border-style:solid; border-width:1px; height:310px; width:600px" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>HUM&#39;s Headwinds</h2>
<p>With a sharp decline expected in Humana&#39;s top-rated Medicare Advantage plan enrollments next year, its revenues are likely to take a hit. This drop is expected to ripple through its partner network, affecting them depending on payment structures. The company has already been dealing with an anticipated membership decline, and this new development further hinders its member growth strategies.</p>
<p>In addition, Humana has been grappling with rising operating expenses. Over the past few years, operating costs surged 10.7% in 2021, 11.5% in 2022, and 14.9% in 2023. The trend has continued, with a 12.8% increase in operating expenses reported in the first half of 2024. The rise is attributed to higher benefits and operating costs, which are likely to pressure profit margins moving forward. Moreover, as senior citizens continue to resume elective procedures post-pandemic, medical costs are set to escalate further, adding to the company&#39;s financial challenges.</p>
<p>Also, its rising debt level is a concern. Long-term debt amounted to $11.7 billion at second-quarter end, up 15% from the figure as of Dec. 31, 2023.&nbsp;Its long-term debt to capital of 41.25% is higher than the industry average of 38.26%.</p>
<h2>Final Words: Steer Clear of HUM Stocks</h2>
<p>Humana is facing significant challenges, including membership decline, rising costs and debt burden. The stock is trading below key moving averages, signaling a bearish trend. With analysts downgrading earnings estimates, investors should approach HUM stock with caution as it shows serious downside potential. It currently carries a Zacks Rank #4 (Sell).</p>
<p><a href="https://www.zacks.com/stock/news/2347052/humana-stock-getting-closer-to-52-week-lows-a-buying-opportunity?cid=CS-BENZ-FT-analyst_blog|52week_high/low-2347052">To read this article on Zacks.com click here.</a></p>


Earnings

Large Cap

Health Care

Analyst Ratings

General

Humana Stock Getting Closer to 52-Week Lows: A Buying Opportunity?

<p>Cantor Fitzgerald  analyst Sarah James   reiterates Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and maintains $90 price target.</p>


Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Centene, Maintains $90 Price Target

<p><strong>Centene's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has fallen 5.05% since its last report. The company recently reported that it has <strong>9.62 million shares sold short</strong>, which is 2.07% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.94 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Centene Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727714722_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Centene has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.38%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Centene's Health Net Subsidiary Selected For California Medicaid Dental Contract In Los Angeles And Sacramento Counties, Starting July 2025

<p>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 5.58% on an annualized basis producing an average annual return of 14.06%. Currently, Centene has a market capitalization of $39.78 billion. </p>
<p><strong>Buying $100 In CNC:</strong> If an investor had bought $100 of CNC stock 20 years ago, it would be worth <strong>$1,562.27</strong> today based on a price of $75.63 for CNC at the time of writing.</p>
<h3>Centene's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726860634_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In This Stock 20 Years Ago Would Be Worth $1,600 Today

Guidance

Centene Expects To Reaffirm 2024 Adjusted EPS Guidance Of Greater Than $6.80 (Est $6.82) At Investors Meet On Sept. 17, 2024 And Bank Of America 2024 Global Healthcare Conference - Filing

<p>Wells Fargo  analyst Stephen Baxter   maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $93 to $91.</p>


Wells Fargo Maintains Overweight on Centene, Lowers Price Target to $91

<p>Consistent with the Company&rsquo;s guidance previously provided on September 4, 2024, the senior management team plans to:</p>
<p>&bull;reiterate the shift of 20 to 30 cents of adjusted diluted EPS from Q3 to Q4. Therefore, the Company projects Q3 adjusted diluted EPS of between $1.31 to $1.41, with the remainder of the 2024 full year adjusted diluted EPS to be realized in Q4; and</p>
<p>&bull;reiterate that, with regard to Medicare Advantage, the Company continues to be encouraged by the progress it has made in the improvement of its stars program performance.</p>


Centene Plans To Reaffirm 2024 Adjusted EPS Guidance Of Greater Than $6.80 (Est $6.83); Reiterate Shift Of 20 To 30 Cents Of Adjusted EPS From Q3 To Q4, With Q3 Adjusted EPS At $1.31 - $1.41 (Est $1.51) - Filing

<p>In the preceding three months, 17 analysts have released ratings for Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Centene, presenting an average target of $88.18, a high estimate of $110.00, and a low estimate of $69.00. Observing a downward trend, the current average is 2.22% lower than the prior average price target of $90.18. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725552042_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Centene among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$69.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Calvin Sternick</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Centene. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Centene compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Centene's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Centene's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CNC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Centene analyst ratings.</strong></a></p>
<h2>Get to Know Centene Better</h2>
<p>Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.</p>
<h3>Financial Milestones: Centene's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Centene's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>5.92%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>2.88%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Centene's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.22%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Centene's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.38%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Centene's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.64</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Centene Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)

<p>Barclays  analyst Andrew Mok   maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $98 to $97.</p>


Barclays Maintains Overweight on Centene, Lowers Price Target to $97

Barclays analyst Andrew Mok CFA maintained a Buy rating on Centene (CNC – Research Report) today and set a price target of $97.00. The company's sh...

Barclays Sticks to Its Buy Rating for Centene (CNC)

The latest update is out from Centene ( ($CNC) ). Centene Corporation has shown significant improvement in their Medicare Advantage Star Ratings, w...

Comments

Centene

Notizie

Ultime notizie per Centene (NYSE:CNC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO